[go: up one dir, main page]

WO2018174668A3 - 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 - Google Patents

인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 Download PDF

Info

Publication number
WO2018174668A3
WO2018174668A3 PCT/KR2018/003489 KR2018003489W WO2018174668A3 WO 2018174668 A3 WO2018174668 A3 WO 2018174668A3 KR 2018003489 W KR2018003489 W KR 2018003489W WO 2018174668 A3 WO2018174668 A3 WO 2018174668A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
reduced affinity
analog complex
receptor
insulin analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/003489
Other languages
English (en)
French (fr)
Other versions
WO2018174668A2 (ko
Inventor
박영진
최인영
정성엽
권세창
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP18772695.5A priority Critical patent/EP3604328A4/en
Priority to BR112019019823A priority patent/BR112019019823A2/pt
Priority to CN201880026742.8A priority patent/CN110536899B/zh
Priority to AU2018239037A priority patent/AU2018239037B2/en
Priority to MX2019011297A priority patent/MX2019011297A/es
Priority to JP2019552181A priority patent/JP7604098B2/ja
Priority to RU2019131593A priority patent/RU2779462C2/ru
Priority to CA3054899A priority patent/CA3054899A1/en
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Priority to US16/495,884 priority patent/US11752216B2/en
Publication of WO2018174668A2 publication Critical patent/WO2018174668A2/ko
Publication of WO2018174668A3 publication Critical patent/WO2018174668A3/ko
Anticipated expiration legal-status Critical
Priority to JP2022205798A priority patent/JP2023024674A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 인슐린 아날로그 결합체 및 이의 용도에 관한 것이다.
PCT/KR2018/003489 2017-03-23 2018-03-23 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 Ceased WO2018174668A2 (ko)

Priority Applications (10)

Application Number Priority Date Filing Date Title
RU2019131593A RU2779462C2 (ru) 2017-03-23 2018-03-23 Комплекс аналога инсулина со сниженной аффинностью к инсулиновому рецептору и его применение
CN201880026742.8A CN110536899B (zh) 2017-03-23 2018-03-23 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途
AU2018239037A AU2018239037B2 (en) 2017-03-23 2018-03-23 Insulin analog complex with reduced affinity for insulin receptor and use thereof
MX2019011297A MX2019011297A (es) 2017-03-23 2018-03-23 Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo.
JP2019552181A JP7604098B2 (ja) 2017-03-23 2018-03-23 インスリン受容体との結合力が減少されたインスリンアナログの結合体及びその用途
EP18772695.5A EP3604328A4 (en) 2017-03-23 2018-03-23 INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY FOR THE INSULIN RECEPTOR AND USE OF IT
BR112019019823A BR112019019823A2 (pt) 2017-03-23 2018-03-23 conjugado, composição farmacêutica para prevenir ou tratar diabetes e método para tratamento de diabetes
CA3054899A CA3054899A1 (en) 2017-03-23 2018-03-23 Insulin analog complex with reduced affinity for insulin receptor and use thereof
US16/495,884 US11752216B2 (en) 2017-03-23 2018-03-23 Insulin analog complex with reduced affinity for insulin receptor and use thereof
JP2022205798A JP2023024674A (ja) 2017-03-23 2022-12-22 インスリン受容体との結合力が減少されたインスリンアナログの結合体及びその用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0037101 2017-03-23
KR20170037101 2017-03-23

Publications (2)

Publication Number Publication Date
WO2018174668A2 WO2018174668A2 (ko) 2018-09-27
WO2018174668A3 true WO2018174668A3 (ko) 2018-12-20

Family

ID=63584449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/003489 Ceased WO2018174668A2 (ko) 2017-03-23 2018-03-23 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도

Country Status (12)

Country Link
US (1) US11752216B2 (ko)
EP (1) EP3604328A4 (ko)
JP (2) JP7604098B2 (ko)
KR (1) KR102629006B1 (ko)
CN (1) CN110536899B (ko)
AR (1) AR111341A1 (ko)
AU (1) AU2018239037B2 (ko)
BR (1) BR112019019823A2 (ko)
CA (1) CA3054899A1 (ko)
MX (1) MX2019011297A (ko)
TW (1) TWI798209B (ko)
WO (1) WO2018174668A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3517544B1 (en) 2016-09-23 2025-01-08 Hanmi Pharm. Co., Ltd. Insulin analog having reduced binding force to insulin receptor, and use thereof
US20200230250A1 (en) * 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
SG11202106168VA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
CN114675019B (zh) * 2022-02-10 2022-12-16 江苏省人民医院（南京医科大学第一附属医院） 一种检测胰岛素受体胞外段抗体的试剂盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140106452A (ko) * 2013-02-26 2014-09-03 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
KR20150087130A (ko) * 2014-01-20 2015-07-29 한미약품 주식회사 지속형 인슐린 및 그 용도
KR20150138101A (ko) * 2014-05-29 2015-12-09 한미약품 주식회사 지속형 인슐린 아날로그 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물
KR20160001391A (ko) * 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) * 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2536040A1 (de) 1975-08-13 1977-02-24 Hoechst Ag Insulin-analoga mit biologischer wirkung
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5422339A (en) 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
EA008433B1 (ru) 2003-07-25 2007-06-29 Конджачем Биотекнолоджис Инк. Производные инсулина длительного действия и способы их использования
EP2239273B1 (en) 2003-11-13 2013-10-09 Hanmi Science Co., Ltd. A pharmaceutical composition comprosing an immunoglobulin fc as a carrier
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
CN102660614A (zh) 2005-08-16 2012-09-12 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
DE102006043673A1 (de) * 2006-09-18 2008-03-27 Robert Bosch Gmbh Synchronmaschine
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
TW200907056A (en) 2007-03-28 2009-02-16 Astrazeneca Ab New method
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
CN101743252A (zh) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、peg化的胰岛素类似物
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2017288A1 (en) 2007-07-16 2009-01-21 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
ES2430042T3 (es) 2007-11-16 2013-11-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009087082A2 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
JP5694779B2 (ja) 2008-01-09 2015-04-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
UA98911C2 (uk) 2009-03-27 2012-06-25 Ґлаксо Ґруп Лімітед Лікувальні злиття та кон'югати інсулінотропних пептидів з доменним антитілом, що зв'язує сироватковий альбумін
WO2011028813A2 (en) 2009-09-01 2011-03-10 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
WO2011075606A2 (en) 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
KR101058209B1 (ko) 2009-12-30 2011-08-22 전자부품연구원 Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
CN103068842B (zh) 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 对胰岛素受体具有高活性的单链胰岛素激动剂
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
BR112013021804A2 (pt) 2011-03-02 2017-03-28 Oerlikon Trading Ag Trübbach "componente corrediço compreendendo revestimento previsto para ficar em contato pelo menos parcialmente com lubrificante, seu sistema tribológico e seu uso"
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
KR101934256B1 (ko) 2011-05-03 2019-01-02 데이진 아라미드 비.브이. 방탄 패널
SG10201606243YA (en) 2011-06-02 2016-09-29 Prolor Biotech Inc Long-acting glp-1/glucagon receptor agonists
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
MX391293B (es) 2011-06-10 2025-03-21 Hanmi Science Co Ltd DERIVADOs DE OXINTOMODULINA NOVEDOSOS Y COMPOSICION FARMACEUTICA PARA TRATAR LA OBESIDAD QUE COMPRENDE LOS MISMOS.
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
KR101577734B1 (ko) 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
US9165768B2 (en) 2011-12-16 2015-10-20 Lg Innotek Co., Ltd. Method for deposition of silicon carbide and silicon carbide epitaxial wafer
EP2804621A4 (en) 2012-01-20 2015-11-18 Univ Case Western Reserve GLUTAMINE-SAFE STABILIZED INSULIN ANALOG
WO2013128003A1 (en) 2012-03-01 2013-09-06 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
MX372833B (es) 2012-11-06 2020-06-25 Hanmi Pharm Co Tld Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina.
PT2963055T (pt) 2013-02-26 2019-07-25 Hanmi Pharm Ind Co Ltd Conugado de insulina específico ao local
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
SG10201800751WA (en) 2013-07-29 2018-03-28 Berkeley Information Tech Pty Ltd Systems and methodologies for managing document access permissions
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR101676542B1 (ko) 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
JP2018531007A (ja) 2015-09-24 2018-10-25 ハンミ ファーマシューティカル カンパニー リミテッド インスリンの製造方法
EP3517544B1 (en) * 2016-09-23 2025-01-08 Hanmi Pharm. Co., Ltd. Insulin analog having reduced binding force to insulin receptor, and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140106452A (ko) * 2013-02-26 2014-09-03 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
KR20150087130A (ko) * 2014-01-20 2015-07-29 한미약품 주식회사 지속형 인슐린 및 그 용도
KR20150138101A (ko) * 2014-05-29 2015-12-09 한미약품 주식회사 지속형 인슐린 아날로그 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물
KR20160001391A (ko) * 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) * 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그

Also Published As

Publication number Publication date
RU2019131593A (ru) 2021-04-23
JP2020511513A (ja) 2020-04-16
US20200101171A1 (en) 2020-04-02
JP2023024674A (ja) 2023-02-16
BR112019019823A2 (pt) 2020-04-22
US11752216B2 (en) 2023-09-12
CN110536899B (zh) 2023-12-12
TW201838647A (zh) 2018-11-01
KR20180108510A (ko) 2018-10-04
JP7604098B2 (ja) 2024-12-23
TWI798209B (zh) 2023-04-11
KR102629006B1 (ko) 2024-01-25
RU2019131593A3 (ko) 2021-07-05
AR111341A1 (es) 2019-07-03
CA3054899A1 (en) 2018-09-27
WO2018174668A2 (ko) 2018-09-27
AU2018239037A1 (en) 2019-10-24
EP3604328A4 (en) 2021-01-06
AU2018239037B2 (en) 2022-05-26
CN110536899A (zh) 2019-12-03
EP3604328A2 (en) 2020-02-05
MX2019011297A (es) 2019-11-12

Similar Documents

Publication Publication Date Title
WO2016081670A3 (en) Insulin receptor partial agonists
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG10202111141WA (en) Anti-claudin 18.2 antibodies and uses thereof
WO2018109174A3 (en) Il-11 antibodies
WO2018081648A3 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
WO2017132580A3 (en) Split inteins with exceptional splicing activity
WO2016205531A3 (en) Anti-her2 antibodies and methods of use
WO2015051030A8 (en) Stabilized polypeptides and uses thereof
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2015038796A3 (en) Secretion of heme-containing polypeptides
WO2018174668A3 (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
EP3733849A4 (en) IMPROVED PROMOTER AND USE THEREOF
EP3585309A4 (en) EYE DEVICES AND THEIR METHODS OF USE
EP3713465A4 (en) MULTIFUNCTIONAL BASE
EP3638280A4 (en) PEPTIDES AND USES THEREOF AS VIRUCIDES
WO2016019306A3 (en) Abrasive article including z-shaped abrasive segments
ZA202005050B (en) Polypeptide, compositions and uses thereof
EP3744358A4 (en) FABRIC FASTENER AND ITS USE
WO2018042255A3 (en) Nutritional compositions and use thereof
EP3509462A4 (en) VARIATION / YEAR MOTION DEVICE AND CHAIR ARRANGEMENT THEREFOR
HK40112580A (zh) 肽、包含肽的组合物及其应用
HK40094578A (zh) 抗密蛋白18.2抗体及其用途
HK40094577A (zh) 抗密蛋白18.2抗体及其用途
HK40103775A (zh) 抗hla-dq2.5 抗体
HK40116404A (zh) 臂组件和座椅装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18772695

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3054899

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 139850140003005154

Country of ref document: IR

ENP Entry into the national phase

Ref document number: 2019552181

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019019823

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018239037

Country of ref document: AU

Date of ref document: 20180323

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018772695

Country of ref document: EP

Effective date: 20191023

ENP Entry into the national phase

Ref document number: 112019019823

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190923